NCT04569032 2026-02-18A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionSeagen Inc.Phase 2 Completed82 enrolled 13 charts
NCT06692452 2026-01-07Tazemetostat Plus CHOP in 1L T-cell LymphomaDana-Farber Cancer InstitutePhase 2 Suspended24 enrolled